帕博利珠单抗联合仑伐替尼用于二线和三线胸膜间皮瘤患者(PEMMELA):一项单臂2期研究
这项在荷兰癌症研究所开展的单臂、单中心2期研究纳入38例铂类-培美曲塞化疗后进展的胸膜间皮瘤患者,接受帕博利珠单抗200 mg静脉注射每3周一次联合仑伐替尼20 mg口服每日一次治疗。研究者评估的客观缓解率为58%(22/38,95%CI 41-74),独立评估为45%(17/38,95%CI 29-62);26%患者发生严重治疗相关不良事件,包括1例治疗相关死亡(心肌梗死)。作者认为该联合方案显示出有前景的抗肿瘤活性但毒性可观,需进一步研究。
要点
- 研究者评估客观缓解率58%(22/38,95%CI 41-74),独立评估45%(17/38,95%CI 29-62)。
- 严重治疗相关不良事件见于10例(26%),含1例治疗相关死亡(心肌梗死)。
- 29例(76%)患者需要至少一次仑伐替尼减量或停药。
核心结论
- 帕博利珠单抗联合仑伐替尼在胸膜间皮瘤患者中显示出有前景的抗肿瘤活性,但毒性可观,与既往研究相似。
- 文献现有证据提示仑伐替尼高起始剂量可获得最佳抗肿瘤活性,但这要求高标准的支持治疗。
- 作者认为帕博利珠单抗联合仑伐替尼值得在胸膜间皮瘤中进一步研究。
研究设计与样本
- 单臂、单中心2期研究,在荷兰阿姆斯特丹荷兰癌症研究所开展。
- 纳入年龄≥18岁、ECOG体能状态0-1、化疗后进展(无既往免疫治疗)、按间皮瘤mRECIST 1.1版可测量病灶的胸膜间皮瘤患者。
- 患者接受帕博利珠单抗200 mg静脉注射每3周一次联合仑伐替尼20 mg口服每日一次,最长2年或直至疾病进展、出现不可接受毒性或撤回知情同意。
- 主要终点为研究者按mRECIST 1.1版评估的客观缓解率;试验注册号NCT04287829,正在招募第二队列。
- 2021年3月5日至2022年1月31日筛查42例,38例纳入主要终点和安全性分析(中位年龄71岁[IQR 65-75],男性33例[87%],女性5例[13%])。
主要发现
- 数据截止2023年1月31日,中位随访17.7个月(IQR 13.8-19.4),38例中22例(58%;95%CI 41-74)获得客观缓解。
- 独立审查显示38例中17例(45%;95%CI 29-62)获得客观缓解。
- 严重治疗相关不良事件发生于10例(26%),包括1例因心肌梗死导致的治疗相关死亡。
- 最常见的治疗相关3级或以上不良事件为高血压(8例[21%])以及厌食和淋巴细胞减少(均4例[11%])。
- 38例中29例(76%)需要至少一次仑伐替尼减量或停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy in patients with pleural mesothelioma who progressed after platinum-pemetrexed chemotherapy. METHODS: In this single-arm, single-centre, phase 2 study, done at the Netherlands Cancer Institute in Amsterdam, The Netherlands, eligible patients (aged ≥18 years) with pleural mesothelioma with an Eastern Cooperative Oncology Group performance status of 0-1, progression after chemotherapy (no previous immunotherapy), and measurable disease according to the modified Response Evaluation Criteria In Solid Tumours (mRECIST) for mesothelioma version 1.1. Patients received 200 mg intravenous pembrolizumab once every 3 weeks plus 20 mg oral lenvatinib once per day for up to 2 years or until disease progression, development of unacceptable toxicity, or withdrawal of consent. The primary endpoint was objective response rate identified by a local investigator according to mRECIST version 1.1. This trial is registered with ClinicalTrials.gov, NCT04287829, and is recruiting for the second cohort. FINDINGS: Between March 5, 2021, and Jan 31, 2022, 42 patients were screened, of whom 38 were included in the primary endpoint and safety analyses (median age 71 years [IQR 65-75], 33 [87%] male and five [13%] female) . At data cutoff (Jan 31, 2023), with a median follow-up of 17·7 months (IQR 13·8-19·4), 22 (58%; 95% CI 41-74) of 38 patients had an objective response. The independent review showed an objective response in 17 (45%; 95% CI 29-62) of 38 patients. Serious treatment-related adverse events occurred in ten (26%) patients, including one treatment-related death due to myocardial infarction. The most common treatment-related grade 3 or worse adverse events were hypertension (eight patients [21%]) and anorexia and lymphopenia (both four patients [11%]). In 29 (76%) of 38 patients, at least one dose reduction or discontinuation of lenvatinib was required. INTERPRETATION: Pembrolizumab plus lenvatinib showed promising anti-tumour activity in patients with pleural mesothelioma with considerable toxicity, similar to that in previous studies. Available evidence from the literature suggests a high starting dose of lenvatinib for optimal anti-tumour activity. This, however, demands a high standard of supportive care. The combination therapy of pembrolizumab and lenvatinib warrants further investigation in pleural mesothelioma. FUNDING: Merck Sharp & Dohme.
引用
- Douma LH, Lalezari F, van der Noort V, et al. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol. 2023. PMID: 37844598. doi:10.1016/S1470-2045(23)00446-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。